International Stem Cell Corp. (ISCO) Reports Strong Financial Results and Conference Call
International Stem Cell Corp., a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today announced financial results for the three and nine months ended September 30, 2013, and conference call details. Q3 2013 Highlights: • Recorded revenues of $1.67 million, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%. • Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 million per month the corresponding…